Evaluation of Votrient in Angiosarcoma

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

26 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-07-31

Study Completion Date

2020-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Open-label phase II trial investigating the efficacy and safety of the investigational combination of pazopanib and paclitaxel.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pazopanib in Advanced and Cisplatin-resistant Germ Cell Tumors

NCT01743482

Germ Cell Tumors Measurable Disease

COMPLETED PHASE2

A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma

NCT01593748

Sarcoma

COMPLETED PHASE2

A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)

NCT01235962

Renal Cell Carcinoma (RCC) Cancer

COMPLETED PHASE3

Study of Pazopanib and Vorinostat in Patients With Advanced Malignancies

NCT01339871

Advanced Cancer

COMPLETED PHASE1

Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine in Treating Patients With Advanced Metastatic Solid Tumors

NCT00307255

Unspecified Adult Solid Tumor, Protocol Specific

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Open-label phase II trial investigating the efficacy and safety of the investigational combination of pazopanib and paclitaxel.This multi-center, open-label, prospective, single arm phase II study was designed to evaluate the clinical efficacy and safety of the experimental combination of pazopanib with paclitaxel in the treatment of patients with advanced or metastatic angiosarcoma.The safety evaluations (physical examination, laboratory checks as defined in protocol, toxicity/adverse event assessment according Eastern Cooperative Oncology Group version 4.0) are scheduled every cycle at day 1, 8, 15 and 29 (= day 1 of the next cycle).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Angiosarcoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pazopanib + Paclitaxel

Paclitaxel administered every 28 days at day 1, day 8 and day 15 as a 2h intravenous infusion in a dose of 70mg/m2 in combination with pazopanib in a daily oral dose of 800mg (2x400mg)

Group Type EXPERIMENTAL

Pazopanib + Paclitaxel

Intervention Type DRUG

pazopanib in combination with paclitaxel in the treatment of patients with advanced or metastatic angiosarcoma.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pazopanib + Paclitaxel

pazopanib in combination with paclitaxel in the treatment of patients with advanced or metastatic angiosarcoma.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects must provide written informed consent prior to performance of study-specific procedures or assessments and must be willing to comply with treatment and follow-up. Note: Procedures conducted as part of the subject's routine clinical management (e.g., blood count, imaging studies) and obtained prior to signing informed consent may be utilized for screening or baseline purposes provided these procedures are conducted as specified in the protocol.
* Age ≥ 18 years
* Life expectancy \> 3 months
* Ability to swallow tablets
* Histological confirmed angiosarcoma, primary and secondary angiosarcoma (e.g. radiation-induced or angiosarcoma in chronical lymphedema) are eligible.
* Tumor must be locally advanced (unresectable) or metastatic. A progression must be documented within a 6-month period prior to screening.
* Eastern Cooperative Oncology Group performance status ≤ 2
* At least one measurable skin lesion or one measurable radiological (CT or MRI) target lesion (RECIST 1.1)
* Adequate organ system function as described in protocol
* A female is eligible to enter and participate in this study if she is either of non childbearing potential (defined in protocol) or childbearing potential with negative pregnancy test within 2 weeks prior to the first dose of study drug and agrees to use adequate contraception (as defined in protocol) during the study and for 30 days after the last dose of study drug.
* All sexually active male patients must agree to use adequate methods of birth control (see protocol) throughout the study and for 30 days after the last dose of study drug.

Exclusion Criteria

* Patients who need an active treatment for another malignant disease other than angiosarcoma
* Prior treatment with taxane within the last 12 months before study entry
* History or clinical evidence of central nervous system (CNS) metastases or leptomeningeal sarcomatosis.(see protocol)
* Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding (see protocol)
* Clinically significant gastrointestinal abnormalities that may affect absorption of investigational product (see protocol)
* Presence of uncontrolled infection
* QT prolongation interval (QTc) \> 480 msec.
* Clinically significant cardiovascular disorders within the past 6 months
* Major surgery or trauma within 28 days prior to first dose of investigational product and/or presence of any non-healing wound, fracture, or ulcer
* Poorly controlled hypertension (see protocol)
* Evidence of active bleeding or bleeding diathesis
* Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels
* Uncontrolled seizures, disorders of the CNS or psychiatric disorders which may put patient safety at risk, prevent giving informed consent or impact the patient's compliance with the use of study medication
* Women who are pregnant or breast feeding
* Patients who are not able or not willing to interrupt the intake of medications that are not allowed according to study protocol for at least 14 days before start of study medication and for the whole study period
* Chemotherapy or radiotherapy within 14 days before start of study medication
* Any ongoing toxicity from prior anti-cancer therapy that is \> grade 1 and/or that is progressing in severity, except alopecia

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No